What is the price-to-earnings ratio of Epizyme?
The price-earnings ratio of Epizyme is currently 1.2.
Epizyme P/S 2024
Epizyme P/S
1.2
Epizyme Dividend yield
Ticker
EPZM
ISIN
US29428V1044
WKN
A1T9L2
As of Jun 7, 2024, Epizyme's P/S ratio stood at 1.2, a 0% change from the 0 P/S ratio recorded in the previous year.
The Epizyme P/S history
Epizyme Aktienanalyse
What does Epizyme do?
Epizyme Inc is an American biotechnology company specializing in the development of therapeutic products for the treatment of cancer and genetic metabolic disorders. The company was founded in 2007 in Cambridge, Massachusetts. Epizyme focuses on developing drugs that target epigenetic changes in cells, which are changes in gene expression caused by changes in DNA structure. Epizyme specializes in the development of inhibitors of histone deacetylase enzymes (HDAC), which suppress the activity of enzymes involved in cell cycle regulation, apoptosis, and DNA repair. The company is divided into different business units focusing on different therapy areas, including oncology, hematologic oncology, and genetic metabolic disorders. In the field of oncology, Epizyme develops drugs for the treatment of blood and lymphatic system cancers such as diffuse large B-cell lymphoma and T-cell lymphoma. In the field of hematologic oncology, the company develops drugs for the treatment of blood disorders like myelodysplastic syndrome and acute myeloid leukemia. In the field of genetic metabolic disorders, Epizyme develops drugs for the treatment of lysosomal storage diseases. The company's business model primarily involves developing its own therapy products and collaborating with other biopharmaceutical companies and the pharmaceutical industry. Epizyme is listed on NASDAQ under the ticker symbol EPZM and has raised over $230 million in funding. Overall, Epizyme is an innovative company with a promising pipeline of drug candidates that works closely with other industry players to achieve its goals. It has established itself as a key player in the biotechnology industry. Epizyme ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Epizyme's P/S Ratio
Epizyme's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Epizyme's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Epizyme's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Epizyme’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Epizyme Stock
How has the price-earnings ratio of Epizyme changed compared to last year?
The price-to-earnings ratio of Epizyme has increased by 0% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Epizyme high compared to other companies?
Yes, the price-to-earnings ratio of Epizyme is high compared to other companies.
How does an increase in the price-earnings ratio of Epizyme affect the company?
An increase in the price-earnings ratio of Epizyme would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Epizyme affect the company?
A decrease in the price-earnings ratio of Epizyme would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Epizyme?
Some factors that influence the price-earnings ratio of Epizyme are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Epizyme pay?
Over the past 12 months, Epizyme paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Epizyme is expected to pay a dividend of 0 USD.
What is the dividend yield of Epizyme?
The current dividend yield of Epizyme is .
When does Epizyme pay dividends?
Epizyme pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Epizyme?
Epizyme paid dividends every year for the past 0 years.
What is the dividend of Epizyme?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Epizyme located?
Epizyme is assigned to the 'Health' sector.
Wann musste ich die Aktien von Epizyme kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Epizyme from 6/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/7/2024.
When did Epizyme pay the last dividend?
The last dividend was paid out on 6/7/2024.
What was the dividend of Epizyme in the year 2023?
In the year 2023, Epizyme distributed 0 USD as dividends.
In which currency does Epizyme pay out the dividend?
The dividends of Epizyme are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Epizyme stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Epizyme
Our stock analysis for Epizyme Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Epizyme Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
